Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase

NCT01147341 is registered in ClinicalTrials.gov with Michael Schiff, MD as lead sponsor.

NCT NCT01147341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01147341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase
Lead sponsor
Michael Schiff, MD
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2010
Completion date
January 31, 2012
Enrollment
37 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis